Diagnosis & Disease Information

Opzelura Cream Approved for Atopic Dermatitis

The Food and Drug Administration has approved Opzelura (ruxolitinib) cream for the short-term and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. The approval was based on data…

Next post in Medicine